LICENSE AGREEMENTLicense Agreement • May 23rd, 2014 • Affimed Therapeutics B.V. • Pharmaceutical preparations • New York
This License Agreement (this “Agreement”), effective as of September 29, 2006 (the “Effective Date”), is entered into by and between XOMA Ireland Limited, a company with limited liability organized under the laws of the Republic of Ireland having offices at Shannon Airport House, Shannon, County Clare, Ireland (with its Affiliates, “XOMA”), and Affimed Therapeutics AG, a company organized under the laws of the Federal Republic of Germany, with offices at Technologiepark, Im Neuenheimer Feld 582, 69120 Heidelberg, Germany (with its Affiliates, “AFFIMED”).
AMENDMENT NO. 1 to the RESEARCH FUNDING AGREEMENT by and between Affimed Therapeutics AG and The Leukemia & Lymphoma SocietyResearch Funding Agreement • May 23rd, 2014 • Affimed Therapeutics B.V. • Pharmaceutical preparations
This Amendment (the “Amendment”) is made as of April 29th, 2014 (the “Amendment Effective Date”), by and between The Leukemia and Lymphoma Society, a New York nonprofit corporation with its principal place of business at 1311 Mamaroneck Avenue, White Plains, New York 10605, United States of America (“LLS”) and Affimed Therapeutics AG, a German limited liability company with its principal place of business at Im Neuenheimer Feld 582, 69120 Heidelberg, Germany (“Affimed”). LLS and Affimed are hereinafter referred to individually as the “Party” and together as the “Parties”.
Amendment to License AgreementLicense Agreement • May 23rd, 2014 • Affimed Therapeutics B.V. • Pharmaceutical preparations
WHEREAS, the Parties have entered into a license agreement, dated March 5 and March 8, 2001, regarding certain patents of DKFZ (the “License Agreement”); and
CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED.License Agreement • May 23rd, 2014 • Affimed Therapeutics B.V. • Pharmaceutical preparations
[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION.
MEMORANDUM OF CLARIFICATION OF: LICENSE AGREEMENT SIGNED BETWEEN DEUTSCHES KREBSFORSCHUNGSZENTRUM AND AFFIMED THERAPEUTICS AG OF MARCH 8, 2001License Agreement • May 23rd, 2014 • Affimed Therapeutics B.V. • Pharmaceutical preparations
Whereas the Deutsches Krebsforschungszentrum (DKFZ) and Affimed Therapeutics AG (Affimed) have entered into a License Agreement of March 8, 2001 (License Agreement), by which the DKFZ has granted Affimed the right to commercialize certain patent rights regarding various antibody libraries and antibodies, and improvements thereto developed by Prof. Melvyn Little and his research group at the DKFZ;
